Global Alzheimer’s Treatment Market
1. Introduction
1.1. Market Definition
1.2. Market Segmentation
1.3. Product Overview
2. Assumptions And Acronyms
3. Research Methodology
3.1. Research Process
3.2. Primary Research
· Manufacturer Front
· Supplier/Distributor Front
· End User Front
3.3. Secondary Research
3.4. Market Size Estimation
4. Executive Summary- Global Alzheimer’s Treatment Market
5. Analysis Of Market Dynamics
5.1. Growth Drivers
5.2. Key Trends
6. Key Market Opportunities
7. Major Roadblocks For The Market Growth
8. Regulatory Landscape
9. Industry Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Epidemiology Analysis
11. Patent Analysis
12. Clinical TrialsAnalysis
13. Comparative Analysis Of Treatment Devices In Development
14. Global Alzheimer’s Treatment Market Outlook
14.1. Market Size And Forecast, 2018-2027
14.1.1. By Value (USD Million)
14.2. Global Alzheimer’s Treatment Market Segmentation, 2018-2027
14.2.1. By Treatment
14.2.1.1. By Drug Class
O Standalone Drugs, 2018-2027 (USD Million)
§ Cholinesterase Inhibitors, 2018-2027 (USD Million)
§ Donepezil (Aricept), 2018-2027 (USD Million)
§ Galantamine (Razadyne), 2018-2027 (USD Million)
§ Rivastigmine (Exelon), 2018-2027 (USD Million)
§ N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
O Combination Drugs, 2018-2027 (USD Million)
14.2.1.2. By Distribution Channel
O Online, 2018-2027 (USD Million)
O Offline, 2018-2027 (USD Million)
§ Hospital Pharmacy, 2018-2027 (USD Million)
§ Retail Pharmacy, 2018-2027 (USD Million)
14.2.2.By Medical Device
14.2.2.1. By Product
O Wearable Device, 2018-2027 (USD Million)
O Non-Wearable Device, 2018-2027 (USD Million)
14.2.2.2.By End-User
O Hospitals, 2018-2027 (USD Million)
O Clinics, 2018-2027 (USD Million)
O Nursing Homes, 2018-2027 (USD Million)
O Home-Care Settings, 2018-2027 (USD Million)
14.2.3.By Region
14.2.3.1. North America Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.1.1.Market Overview
14.2.3.1.2.Market Size, 2018-2027 (USD Million)
14.2.3.1.3.Assessment Of Macroeconomic Factors
14.2.3.1.4.Market Segmentation
§ By Treatment
O By Drug Class
§ Standalone Drugs, 2018-2027 (USD Million)
· Cholinesterase Inhibitors, 2018-2027 (USD Million)
· Donepezil (Aricept), 2018-2027 (USD Million)
· Galantamine (Razadyne), 2018-2027 (USD Million)
· Rivastigmine (Exelon), 2018-2027 (USD Million)
· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
§ Combination Drugs, 2018-2027 (USD Million)
O By Distribution Channel
§ Online, 2018-2027 (USD Million)
§ Offline, 2018-2027 (USD Million)
· Hospital Pharmacy, 2018-2027 (USD Million)
· Retail Pharmacy, 2018-2027 (USD Million)
§ By Medical Device
O By Product
§ Wearable Device, 2018-2027 (USD Million)
§ Non-Wearable Device, 2018-2027 (USD Million)
O By End-User
§ Hospitals, 2018-2027 (USD Million)
§ Clinics, 2018-2027 (USD Million)
§ Nursing Homes, 2018-2027 (USD Million)
§ Home-Care Settings, 2018-2027 (USD Million)
§ By Country
O Us, 2018-2027 (USD Million)
O Canada, 2018-2027 (USD Million)
14.2.3.2.Europe Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.2.1.Market Overview
14.2.3.2.2. Market Size, 2018-2027 (USD Million)
14.2.3.2.3. Assessment Of Macroeconomic Factors
14.2.3.2.4. Market Segmentation
§ By Treatment
O By Drug Class
§ Standalone Drugs, 2018-2027 (USD Million)
· Cholinesterase Inhibitors, 2018-2027 (USD Million)
· Donepezil (Aricept), 2018-2027 (USD Million)
· Galantamine (Razadyne), 2018-2027 (USD Million)
· Rivastigmine (Exelon), 2018-2027 (USD Million)
· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
§ Combination Drugs, 2018-2027 (USD Million)
O By Distribution Channel
§ Online, 2018-2027 (USD Million)
§ Offline, 2018-2027 (USD Million)
· Hospital Pharmacy, 2018-2027 (USD Million)
· Retail Pharmacy, 2018-2027 (USD Million)
§ By Medical Device
O By Product
§ Wearable Device, 2018-2027 (USD Million)
§ Non-Wearable Device, 2018-2027 (USD Million)
O By End-User
§ Hospitals, 2018-2027 (USD Million)
§ Clinics, 2018-2027 (USD Million)
§ Nursing Homes, 2018-2027 (USD Million)
§ Home-Care Settings, 2018-2027 (USD Million)
§ By Country
O Uk, 2018-2027 (USD Million)
O Germany, 2018-2027 (USD Million)
O Italy, 2018-2027 (USD Million)
O France, 2018-2027 (USD Million)
O Spain, 2018-2027 (USD Million)
O Russia, 2018-2027 (USD Million)
O Rest Of Europe, 2018-2027 (USD Million)
14.2.3.3. Asia Pacific Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.3.1. Market Overview
14.2.3.3.2. Market Size, 2018-2027 (USD Million)
14.2.3.3.3. Assessment Of Macroeconomic Factors
14.2.3.3.4. Market Segmentation
§ By Treatment
O By Drug Class
§ Standalone Drugs, 2018-2027 (USD Million)
· Cholinesterase Inhibitors, 2018-2027 (USD Million)
· Donepezil (Aricept), 2018-2027 (USD Million)
· Galantamine (Razadyne), 2018-2027 (USD Million)
· Rivastigmine (Exelon), 2018-2027 (USD Million)
· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
§ Combination Drugs, 2018-2027 (USD Million)
O By Distribution Channel
§ Online, 2018-2027 (USD Million)
§ Offline, 2018-2027 (USD Million)
· Hospital Pharmacy, 2018-2027 (USD Million)
· Retail Pharmacy, 2018-2027 (USD Million)
§ By Medical Device
O By Product
§ Wearable Device, 2018-2027 (USD Million)
§ Non-Wearable Device, 2018-2027 (USD Million)
O By End-User
§ Hospitals, 2018-2027 (USD Million)
§ Clinics, 2018-2027 (USD Million)
§ Nursing Homes, 2018-2027 (USD Million)
§ Home-Care Settings, 2018-2027 (USD Million)
§ By Country
O China, 2018-2027 (USD Million)
O India, 2018-2027 (USD Million)
O Japan, 2018-2027 (USD Million)
O South Korea, 2018-2027 (USD Million)
O Indonesia, 2018-2027 (USD Million)
O Australia, 2018-2027 (USD Million)
O Rest Of Asia Pacific, 2018-2027 (USD Million)
14.2.3.4.Latin America Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.4.1.Market Overview
14.2.3.4.2. Market Size, 2018-2027 (USD Million)
14.2.3.4.3. Assessment Of Macroeconomic Factors
14.2.3.4.4. Market Segmentation
§ By Treatment
O By Drug Class
§ Standalone Drugs, 2018-2027 (USD Million)
· Cholinesterase Inhibitors, 2018-2027 (USD Million)
· Donepezil (Aricept), 2018-2027 (USD Million)
· Galantamine (Razadyne), 2018-2027 (USD Million)
· Rivastigmine (Exelon), 2018-2027 (USD Million)
· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
§ Combination Drugs, 2018-2027 (USD Million)
O By Distribution Channel
§ Online, 2018-2027 (USD Million)
§ Offline, 2018-2027 (USD Million)
· Hospital Pharmacy, 2018-2027 (USD Million)
· Retail Pharmacy, 2018-2027 (USD Million)
§ By Medical Device
O By Product
§ Wearable Device, 2018-2027 (USD Million)
§ Non-Wearable Device, 2018-2027 (USD Million)
O By End-User
§ Hospitals, 2018-2027 (USD Million)
§ Clinics, 2018-2027 (USD Million)
§ Nursing Homes, 2018-2027 (USD Million)
§ Home-Care Settings, 2018-2027 (USD Million)
§ By Country
O Brazil, 2018-2027 (USD Million)
O Mexico, 2018-2027 (USD Million)
O Rest Of Latin America, 2018-2027 (USD Million)
14.2.3.5. Middle East & Africa Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.5.1.Market Overview
14.2.3.5.2. Market Size, 2018-2027 (USD Million)
14.2.3.5.3. Assessment Of Macroeconomic Factors
14.2.3.5.4. Market Segmentation
§ By Treatment
O By Drug Class
§ Standalone Drugs, 2018-2027 (USD Million)
· Cholinesterase Inhibitors, 2018-2027 (USD Million)
· Donepezil (Aricept), 2018-2027 (USD Million)
· Galantamine (Razadyne), 2018-2027 (USD Million)
· Rivastigmine (Exelon), 2018-2027 (USD Million)
· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
§ Combination Drugs, 2018-2027 (USD Million)
O By Distribution Channel
O By Product
O By End-User
§ By Country
O Israel, 2018-2027 (USD Million)
O Saudi Arabia, 2018-2027 (USD Million)
O UAE, 2018-2027 (USD Million)
O South Africa, 2018-2027 (USD Million)
O Rest Of Middle East & Africa, 2018-2027 (USD Million)
15.Competitive Structure
15.1.Detailed Overview
15.2.Market Share
15.3.Assessment Of Key Product Offerings
15.4.Analysis Of Growth Strategies
15.5. Key Collaborations And Joint Ventures
15.6. Key Mergers And Acquisitions
15.7. Recent News And Developments
15.8. Key Clients And Partners
15.9. Exhaustive Analysis On Key Financial Indicators
15.10. Company Profiles Of Global Alzheimer’s Treatment Market
15.10.1. Neuroem Therapeutics, Inc.
15.10.2. Neuronix
15.10.3. Daiichi Sankyo Company Limited
15.10.4.H. Lundbeck A/S
15.10.5.Pfizer Inc.
15.10.6.Abbvie Inc
15.10.7.Eli Lilly And Company
15.10.8.Allergan, Inc.
15.10.9.Janssen Pharmaceuticals, Inc.
15.10.10. Other Market Players Strategic 16. Recommendations